y*****l
发帖数: 5997 | 1 Pre market up.
Spectrum Pharmaceuticals Announces Record Revenue and Record Profit in First
Quarter 2011
28 minutes ago - BIZ via Comtex
BusinessWire--Anticipate Reporting a Record Quarterly Profit in the First
Quarter 2011 Second Consecutive Profitable Quarter
--FUSILEV(R) sNDA For Use In Advanced Metastatic Colorectal Cancer is
Currently Under Review by the FDA PDUFA Action Date -- This Week -- April 29
, 2011
--ZEVALIN(R) Prior Approval Supplement for the Removal of the Bioscan
Requirement Cu... 阅读全帖 |
|
g***y
发帖数: 1025 | 2 7:06AM Spectrum Pharma: FDA approves the removal of the Bioscan requirement
for ZEVALIN treatment (SPPI) 12.18 : Co, received approval from the FDA on
November 18, 2011 to remove the pre-treatment biodistribution evaluation
requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan
before administering the ZEVALIN therapeutic dose. This pre-treatment
biodistribution evaluation requirement is more commonly referred to as the
bioscan. |
|
h*******i
发帖数: 5 | 3 找有机化学或药物化学的博后，详见如下：
Chemistry for Molecular Imaging (344)
The UT Southwestern Medical Center has recently established the Cyclotron
and Radiochemistry Program, which encompasses a GE PETTrace cyclotron, three
small animal scanners (a Siemens Inveon PET/CT Multimodality System, a
Bioscan NanoSPECT/CT Plus system, and an ASPECT M2 1T MRI system), and state
-of-the-art chemistry and radiochemistry laboratories and quality assurance
facilities equipped with high-end analytical instruments including ... 阅读全帖 |
|
h*******i
发帖数: 5 | 4 找有机化学或药物化学的博后，详见如下：
Chemistry for Molecular Imaging (344)
The UT Southwestern Medical Center has recently established the Cyclotron
and Radiochemistry Program, which encompasses a GE PETTrace cyclotron, three
small animal scanners (a Siemens Inveon PET/CT Multimodality System, a
Bioscan NanoSPECT/CT Plus system, and an ASPECT M2 1T MRI system), and state
-of-the-art chemistry and radiochemistry laboratories and quality assurance
facilities equipped with high-end analytical instruments including ... 阅读全帖 |
|
w****a
发帖数: 12 | 5 Biotech Calendar: 2011 FDA Drug Approvals
05/25/11
BOSTON (TheStreet) -- The 2011 FDA drug approval calendar has been updated.
For easier reference, this regulatory calendar is organized in chronological
order based on the drug approval decision date. Information on pending FDA
advisory panels is also included.
Optimer Pharmaceuticals(OPTR_)
Drug/indication: Dificid for Clostridium difficile infection
FDA approval decision date: May 30, 2011
GlaxoSmithKline(GSK_) and Valeant Pharmaceuticals(VRX_... 阅读全帖 |
|
N*S
发帖数: 213 | 6 【 以下文字转载自 pennystock 俱乐部 】
发信人: NBS (张有才), 信区: pennystock
标 题: SPPI 出了
发信站: BBS 未名空间站 (Tue Nov 15 13:52:41 2011, 美东)
@$12.68。有的童鞋要注意这个月的bioscan removal FDA. 个人觉得会过， 但会sell
on news. |
|
h*******i
发帖数: 5 | 7 找有机化学或药物化学的博后。 详见如下：
Chemistry for Molecular Imaging (344)
The UT Southwestern Medical Center has recently established the Cyclotron
and Radiochemistry Program, which encompasses a GE PETTrace cyclotron, three
small animal scanners (a Siemens Inveon PET/CT Multimodality System, a
Bioscan NanoSPECT/CT Plus system, and an ASPECT M2 1T MRI system), and state
-of-the-art chemistry and radiochemistry laboratories and quality assurance
facilities equipped with high-end analytical instruments including... 阅读全帖 |
|
y*****l
发帖数: 5997 | 8 UPDATE 1-Spectrum Pharma says cancer drug shows promise; shrs up
SPECTRUM PHARMACEUTICALS, INC.
SPPI.O
$5.41
+0.46+9.29%
2:00pm CST
Mon Dec 6, 2010 5:51pm EST
* Mid-stage trial sees 84 pct response rate
* Late-stage study shows 35 months progression-free survival
* Shares up 10 pct
Dec 6 (Reuters) - Spectrum Pharmaceuticals Inc (SPPI.O) said a mid-stage
trial of its injection for non-Hodgkin's lymphoma (NHL), a type of cancer,
as a first-line therapy showed positive results, sending its shares u... 阅读全帖 |
|
y*****l
发帖数: 5997 | 9 http://www.thestreet.com/story/11131722/1/biotech-calendar-2011
Biotech Calendar: 2011 FDA Drug Approvals
By Adam Feuerstein 05/25/11
BOSTON (TheStreet) -- The 2011 FDA drug approval calendar has been updated.
For easier reference, this regulatory calendar is organized in chronological order based on the drug approval decision date. Information on pending FDA advisory panels is also included.
Optimer Pharmaceuticals(OPTR_)
Drug/indication: Dificid for Clostridium difficile infection
FDA approval... 阅读全帖 |
|
y*****l
发帖数: 5997 | 10 http://www.thestreet.com/story/11131722/1/biotech-calendar-2011
Stock quotes in this article:SPPI, CTIC, TSPT, SGEN, ANX, PATH, OPTR
http://finviz.com/screener.ashx?v=341&t=SPPI,CTICD,TSPT,SGEN,AN
Biotech Calendar: 2011 FDA Drug Approvals
By Adam Feuerstein 05/25/11
BOSTON (TheStreet) -- The 2011 FDA drug approval calendar has been updated.
For easier reference, this regulatory calendar is organized in chronological
order based on the drug approval decision date. Information on pending FDA
advis... 阅读全帖 |
|
y*****l
发帖数: 5997 | 11 http://www.thestreet.com/_yahoo/story/11215926/1/biotech-calend
Updated with corrected FDA approval decision date for Roche's melanoma drug
Zelboraf. It's Oct. 28, 2011, not Nov. 11, 2011, as previously reported.
BOSTON (TheStreet) -- The 2011 FDA drug approval calendar has been updated
and extended through the first quarter of 2012.
For easier reference, this regulatory calendar is organized in chronological
order based on the drug approval decision date. Information on pending FDA
advisory pan... 阅读全帖 |
|
j*****2
发帖数: 306 | 12 has a HUGE position at SPPI, any opinion of NOV 20's BIOSCAN REMOVE, and the
2 NDA file next year.
can this be next QCOR or even better?? |
|
N*S
发帖数: 213 | 13 @$12.68。有的童鞋要注意这个月的bioscan removal FDA. 个人觉得会过， 但会sell
on news. |
|
y*****l
发帖数: 5997 | 14 债务忧虑拖累美股盘中下跌
美股周一盘中下跌。美国国会减赤联合特别委员会(简称「超级委员会」)将公布1.2兆
美元的降低赤字方案，但市场一致不看好结果。超级委员会的结果可能导致未来十年军
事支出大减六千亿美元。但军事类股已大幅下滑，所以委员会的结果对该类股可能不会
造成太大的影响。
道琼工业指数盘中下跌291.27点，来到11504.70点，跌幅2.48%。那斯达克指数下跌61.
36点，来到2510.76点，跌幅2.40%。S&P 500下跌27.57点，来到1187.75点，跌幅2.30%
。
联邦储备银行芝加哥分行周一公布，十月份全国活动指数微幅上升至负0.13点，优於九
月份的负0.20点。
美国全国不动产商协会周一公布，十月份成屋销售上升1.4%，经季节性调整後的年率为
497万户，优於九月的490万户。分析师原先预估十月份销售480万户。
Resource America(REXI)宣布，旗下商务金融子公司LEAF Commercial Capital获得Eos
Partners与其关系企业注入1.25亿美元资本。
Yingli Green Energy(YGE)与CI... 阅读全帖 |
|
b*****h
发帖数: 783 | 15 sppi 3／1号的er应该继续保持增长，后面就比较难说了。
1。Zevalin 在bioscan 取消后应该会有些增长，由于市场主要被rituxan占有，
Zevalin上升空间偏向有限。
2。它的目前主要收入来源fusilev 始终受到generic 恢复产量的危险，
3。sppi 近期买下了Zevalin 的全球销售权，准备全球推广（不确定的成本和模式对短
期投资人来说是不利的）。
4。license 了GCSF，向癌症的supportive care 方向拓展。
5。pipeline 里还有两个后期的抗癌药。
公司strategy 很不错，长期发展有潜力，但是短期有不少不确定因素。 |
|
